



Kilitch Drugs (India) Ltd.

October 7, 2017

To,
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To,
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Dear Sirs,

Sub: Statement of Investor Complaints- Regulation 13 of SEBI (LODR) Regulation, 2015– Quarter ended 30thSeptember, 2017

Pursuant to Regulation 13 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statement of the investors complaints of the company for the quarter and half year ended 30th September, 2017 is as under:

No. of investor complaints pending at the beginning of the quarter (01.07.2017)	00
No. of investor complaints received during the quarter	04
No. of investor complaints disposed off during the quarter	04
No. of investor complaints remaining unresolved at the end of the quarter (30.09.2017)	00

Further, please find enclosed below the statement on Investor Complaints as furnished by registrar and share transfer agents for relevant period.

The above is for your information and record.

Thanking you,

Yours truly,
For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director
DIN: 00147876



06th Oct 2017

To
Jill Gada
Company Secretary.
Kilitch Drugs (India) Limited.
C-301/2 MIDC TTC,
Industrial Area, Pawane,
Thane 400 705

Dear Sir,


Sub : Investor Grievance report for the period 01.07.2017 to 30.09.2017.

Please refer the below Investor Grievance report for the period 01.07.2017 to 30.09.2017

Description of Investor Grievances for the quarter	No of Grievances
Total Grievances pending at the beginning of the quarter	NIL
Letters N/R/ of D/w, Interest / Redemption warrant	NIL
Correction in Refund Instrument	NIL
N.S.E	04
B.S.E	NIL
SEBI	NIL
Total Grievances attended	04
Total Grievances pending at the end of the quarter	NIL

Thanking You.

Yours faithfully
For Link Intime India Private Limited



Authorised Signatory